Researchers use green tea to 'treat' persons with Down's syndrome
Print Edition
A chemical in green tea has been shown to improve cognitive ability in persons with Down’s syndrome, scientists and doctors said.
In a year-long clinical trial, the treatment led to improved scores on memory and behavior tests, they reported in a study, published in the The Lancet Neurology.
The positive impact remained six months after the trial ended.
Brain scans revealed that the compound, called epigallocatechin gallate, altered the way neurons in the brain connect with one another.
“This is the first time that a treatment has shown efficacy in the cognitive improvement of persons with this syndrome,” said Mara Dierssen, senior author of the study and a researcher at the Centre for Genomic Regulation in Barcelona.
While significant, she added in a statement, the results should not be interpreted as a “cure.”
“But it may be a tool to improve these individuals’ quality of life.”
Experts not involved in the study described it as “exciting” and “an important piece of work.”
At the same time, they cautioned, the findings must be validated in additional trials.
Down’s syndrome is the most common genetic form of intellectual disability, and afflicts approximately one in 1,000 people, according to the World Health Organization.
Also known as trisomy 21, the condition is caused by the presence of an extra, or third, copy of chromosome number 21. In Down’s syndrome, the extra copy causes some of the genes in chromosome 21 to be “over-expressed,” leading to reduced cognitive abilities and other health problems.
In earlier experiments with mice designed to mimic Down’s, Dierssen had shown that inhibiting one of these genes, DYRK1A, improved function and development in the brain.
But the technique used — gene therapy — was not an option for humans, so the researchers turned to the green tea compound.
In the trials, 84 young adults with Down’s syndrome were split into two groups.
One was given a decaffeinated green tea supplement containing 45 percent epigallocatechin gallate, along with weekly online cognitive training.
The second group had the same training, but ingested a look-alike placebo instead of the supplement.
There was little-to-no change in most categories, but in a few — the ability to remember patterns, verbal recall, adaptive behavior — the “green tea” group scored significantly better.
Moreover, they improved over time.
“It’s exciting that an understanding of the genetic neurobiology of Down’s syndrome is leading to the possibility of disorder-specific treatments,” said David Nutt, head of the Centre for Neuropsychopharmacology at Imperial College London.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
